In line with these immune mechanism observations, rituximab’s ability to target B cells and modulate T-cell responses may explain its effectiveness in MGN, particularly in patients with high PLA2R-Ab titers. The gene discussed is PLA2R1; the disease is idiopathic membranous glomerulonephritis.